What Happened?
New Providence, NJ-based ADC-Therapeutics Appointed Kristen Harrington-Smith as Chief Commercial Officer
About the Company
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
About the Person
Kristen Harrington-Smith is Chief Commercial Officer at ADC Therapeutics. Previously, Kristen held various senior HR leadership roles in the industry.
Info Source
News
Short Profile